Cefetamet is an antibacterial broad spectrum Cephalosporin antibiotic prescribed for susceptible infections.
Cefetamet has in-vitro activity against bacteria, such as Haemophilus influenza, Streptococcus pneumoniae, Moraxella catarrhalis, and others, by inhibiting bacterial cell wall synthesis.

The global Cefetamet Pivoxil Tablets market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Cefetamet Pivoxil Tablets volume and value at global level, regional level and company level. From a global perspective, this report represents overall Cefetamet Pivoxil Tablets market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Cefetamet Pivoxil Tablets in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Cefetamet Pivoxil Tablets manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Merck
Incepta Pharmaceuticals
Chugai Pharmaceutical
BOC Sciences
Northeast Healthcare
Zydus Cadila Healthcare
Nhan Sinh Pharmaceuticals
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
6 Months-3 Years
3-9 Years
9-12 Years
Over 12 Years

Segment by Application
Ear, Nose and/or Throat Infections
Otitis Media
Sinusitis
Pharyngo-Tonsillitis
Lower Respiratory Tract Infections
Acute Bacterial Exacerbation of Chronic Bronchitis
Tracheo-Bronchitis
Pneumonia
Urinary Tract Infections
Gonococcal Urethritis in Men